

PATENT
Attorney Docket No. 205884

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ullrich et al.

Art Unit: Unassigned

U.S. National Phase of:
PCT/EP99/00405

Examiner: Unassigned

International Filing Date:
January 22, 1999

For: USE OF INHIBITORS FOR THE
TREATMENT OF RTK-
HYPERFUNCTION-INDUCED
DISORDERS, PARTICULARLY
CANCER

PRELIMINARY AMENDMENT

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Prior to the examination of the above-identified patent application, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE CLAIMS:

✓ Please cancel claims 1-32.

Please add the following new claims:

21
33. A method for the prophylactic and/or therapeutic treatment of a receptor tyrosine kinase (RTK)-hyperfunction-induced disorder in a mammal, which method comprises administering to a mammal in need thereof an effective amount of at least one inhibitor of fibroblast growth factor receptor-4 (FGFR-4), wherein said RTK-hyperfunction-induced disorder is treated prophylactically and/or therapeutically.